Circassia Pharmaceuticals Statistics
Want to see GB:NIOX full AI Analyst Report?
Circassia Pharmaceuticals (NIOX) Stock Statistics & Valuation Metrics
Total Valuation
Circassia Pharmaceuticals has a market cap or net worth of GBX 261.00M. The enterprise value is GBX 237.97M.
- Market Cap
- GBX 261.00M
- Enterprise Value
- GBX 237.97M
Share Statistics
Circassia Pharmaceuticals has 405,273,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 405,273,130
- Owned by Insiders
- 2.22%
- Owned by Institutions
- 0.49%
Financial Efficiency
Circassia Pharmaceuticals’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 9.75%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 9.75%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 502.06K
- Profits Per Employee
- 72.16K
- Employee Count
- 97
- Asset Turnover
- 0.64
- Inventory Turnover
- 3.82
Valuation Ratios
The current PE Ratio of Circassia Pharmaceuticals is 38.08. Circassia Pharmaceuticals’s PEG ratio is 1.13.
- PE Ratio
- 38.08
- PS Ratio
- 5.43
- PB Ratio
- 4.03
- Price to FCF
- 20.62
- Price to Operating Cash Flow
- 20.99
- PEG Ratio
- 1.13
Income Statement
In the last 12 months, Circassia Pharmaceuticals had revenue of 48.70M and earned 7.00M in profits. Earnings per share was 0.02.
- Revenue
- 48.70M
- Gross Profit
- 29.60M
- Operating Income
- 10.70M
- Pretax Income
- 11.20M
- Net Income
- 7.00M
- EBITDA
- 14.80M
- Earnings Per Share (EPS)
- 0.02
Cash Flow
In the last 12 months, operating cash flow was 12.70M and capital expenditures -200,000, giving a free cash flow of 12.50M billion.
- Operating Cash Flow
- 12.70M
- Free Cash Flow
- 12.50M
- Free Cash Flow per Share
- 0.03
Dividends & Yields
Circassia Pharmaceuticals pays an annual dividend of GBX 1.55, resulting in a dividend yield of 2.44%
- Dividend Per Share
- GBX 1.55
- Dividend Yield
- 2.44%
- Payout Ratio
- 91.18%
- Free Cash Flow Yield
- 4.85%
- Earnings Yield
- 2.63%
Stock Price Statistics
- Beta
- 0.40
- 52-Week Price Change
- -10.42%
- 50-Day Moving Average
- 67.04
- 200-Day Moving Average
- 62.19
- Relative Strength Index (RSI)
- 40.35
- Average Volume (3m)
- 793.47K
Important Dates
Circassia Pharmaceuticals upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 29, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- May 21, 2026
Financial Position
Circassia Pharmaceuticals as a current ratio of 3.81, with Debt / Equity ratio of 1.36%
- Current Ratio
- 3.81
- Quick Ratio
- 3.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.28
- Interest Coverage Ratio
- 53.50
Taxes
In the past 12 months, Circassia Pharmaceuticals has paid 4.20M in taxes.
- Income Tax
- 4.20M
- Effective Tax Rate
- 0.38
Enterprise Valuation
Circassia Pharmaceuticals EV to EBITDA ratio is 16.44, with an EV/FCF ratio of 19.33.
- EV to Sales
- 5.09
- EV to EBITDA
- 16.44
- EV to Free Cash Flow
- 19.33
- EV to Operating Cash Flow
- 19.03
Balance Sheet
Circassia Pharmaceuticals has GBX 16.80M in cash and marketable securities with GBX 700.00K in debt, giving a net cash position of GBX 16.10M billion.
- Cash & Marketable Securities
- GBX 16.80M
- Total Debt
- GBX 700.00K
- Net Cash
- GBX 16.10M
- Net Cash Per Share
- GBX 0.04
- Tangible Book Value Per Share
- GBX 0.10
Margins
Gross margin is 60.42%, with operating margin of 21.89%, and net profit margin of 14.74%.
- Gross Margin
- 60.42%
- Operating Margin
- 21.89%
- Pretax Margin
- 23.79%
- Net Profit Margin
- 14.74%
- EBITDA Margin
- 30.95%
- EBIT Margin
- 21.89%
Analyst Forecast
The average price target for Circassia Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 3.26%
- EPS Growth Forecast
- 32.54%
Scores
- Smart Score
- 5
- AI Score
- 73
